147 related articles for article (PubMed ID: 15350353)
1. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
[TBL] [Abstract][Full Text] [Related]
2. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
[TBL] [Abstract][Full Text] [Related]
3. The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer.
Shibata J; Murakami K; Aoyagi Y; Oie S; Hashimoto A; Suzuki K; Sano M; Wierzba TT; Yamada Y
Anticancer Res; 2000; 20(5B):3583-90. PubMed ID: 11131666
[TBL] [Abstract][Full Text] [Related]
4. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
Sako T; Nakayama Y; Minagawa N; Inoue Y; Onitsuka K; Katsuki T; Tsurudome Y; Shibao K; Hirata K; Nagata N; Ohie S; Kohno K; Itoh H
In Vivo; 2005; 19(1):125-32. PubMed ID: 15796164
[TBL] [Abstract][Full Text] [Related]
5. 4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
Inoue Y; Nakayama Y; Sako T; Minagawa N; Abe Y; Nagato M; Kadowaki K; Katsuki T; Matsumoto K; Tsurudome Y; Shibao K; Hirata K; Nagata N
In Vivo; 2007; 21(2):381-7. PubMed ID: 17436592
[TBL] [Abstract][Full Text] [Related]
6. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Murakami K; Matsuura T; Sano M; Hashimoto A; Yonekura K; Sakukawa R; Yamada Y; Saiki I
Clin Exp Metastasis; 1998 Oct; 16(7):633-43. PubMed ID: 9932610
[TBL] [Abstract][Full Text] [Related]
7. Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model.
Eshima K; Fukaya S; Sugimoto A; Mori T; Yokoi H; Yamamoto Y; Sugiura S; Honda S; Masuko N; Murakami K; Yamasaki Y; Kagechika H
Tumour Biol; 2009; 30(1):1-7. PubMed ID: 19142034
[TBL] [Abstract][Full Text] [Related]
8. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells.
Fujimoto K; Hosotani R; Doi R; Wada M; Lee JU; Koshiba T; Miyamoto Y; Tsuji S; Nakajima S; Imamura M
Int J Cancer; 1999 May; 81(4):637-44. PubMed ID: 10225456
[TBL] [Abstract][Full Text] [Related]
9. Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
Sakukawa R; Murakami K; Ikeda T; Yamada Y; Saiki I
Oncol Res; 1998; 10(6):287-93. PubMed ID: 9848099
[TBL] [Abstract][Full Text] [Related]
10. TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
Murakami K; Yamaura T; Suda K; Ohie S; Shibata J; Toko T; Yamada Y; Saiki I
Jpn J Cancer Res; 1999 Nov; 90(11):1254-61. PubMed ID: 10622538
[TBL] [Abstract][Full Text] [Related]
11. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
[TBL] [Abstract][Full Text] [Related]
13. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
Shibata J; Murakami K; Wierzba K; Aoyagi Y; Hashimoto A; Sano M; Toko T; Yamada Y
Anticancer Res; 2000; 20(5A):3169-76. PubMed ID: 11062739
[TBL] [Abstract][Full Text] [Related]
15. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Matsumura N; Mandai M; Okamoto T; Yamaguchi K; Yamamura S; Oura T; Baba T; Hamanishi J; Kang HS; Matsui S; Mori S; Murphy SK; Konishi I
Cancer Sci; 2010 Dec; 101(12):2658-63. PubMed ID: 21040214
[TBL] [Abstract][Full Text] [Related]
17.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
18. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T
Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536
[TBL] [Abstract][Full Text] [Related]
19. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span.
Murakami K; Wierzba K; Sano M; Shibata J; Yonekura K; Hashimoto A; Sato K; Yamada Y
Clin Exp Metastasis; 1998 May; 16(4):323-31. PubMed ID: 9626811
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
